ReviewFrontiers in immunology2026
Microbiota-driven epigenetic programming of local immunity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The maintenance of local immunity requires stable tissue adaptation, implying that persistent environmental cues must continuously reinforce niche-specific immune programs. Microbiota-derived metabolites are increasingly recognized as such cues, acting not merely as metabolic byproducts but as epigenetic inputs that regulate histone modifications, DNA and histone methylation, and non-coding RNA networks. Through these epigenetic mechanisms, microbial metabolites reprogram key immune populations by promoting tolerogenic or immunostimulatory states, tuning effector and memory differentiation, and reshaping subset-specific functions in a tissue-dependent manner. Tissue-level studies have further shown that this microbiota-epigenome crosstalk influences barrier tolerance in the gut and skin, antiviral and inflammatory responses in the lung, metabolic and fibrogenic programs in the liver, and microglial immune tone in the brain. However, studies establishing a complete causal chain from a defined commensal source and metabolite availability to sensing or uptake pathway, chromatin-modifying enzyme or epigenetic mark, target gene locus, responding immune cell type, and validated immune outcome remain to be limited. Future studies should integrate causal microbial genetics, longitudinal metabolomics, cell-type-resolved epigenomics, and human validation to distinguish causal mechanisms from associative findings and enable safe tissue- and patient-specific therapeutic translation. This review therefore outlines the microbiota-metabolite-epigenome axis as a unifying framework for local immunity while emphasizing the mechanistic gaps that must be addressed to develop effective therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.